Pharmaceuticals
PRISM BioLab and Receptor.AI Announce Drug Discovery Collaboration Agreement
— Advancing the Discovery of Novel Therapies and Building an Integrated Drug Discovery Platform by Combining PPI Science with AI — TOKYO, March 12, 2026 /PRNewswire/ -- PRISM BioLab Co., Ltd. ("PRISM") and Receptor.AI Inc. today announced that they have entered into a drug discovery collaboratio...
2026-03-13 08:00
3426
Emerald Clinical Trials Honored with 2026 Asia Pacific Biopharma Excellence Award for Outstanding Patient Recruitment & Engagement
SINGAPORE, March 12, 2026 /PRNewswire/ -- Emerald Clinical Trials
2026-03-12 21:02
3918
ImmunoForge to Conduct Strategic Partnering at Bio-Europe Spring 2026
* Conducting global licensing partnering of LMT15, a proprietary BBB Shuttle platform * Also discussing global out-licensing of Phase 2 stage new drugs PF1801 and PF1804 SEOUL, South Korea, March 12, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd. , a biopharmaceutical company developing treatments...
2026-03-12 16:58
4751
Nuance Pharma Announces Approval of Ohtuvayre® (ensifentrine) in Hong Kong SAR, China
Approval marks the second regulatory approval outside of the U.S. Food and Drug Administration, further expanding access to COPD patients in select Special Administrative Regions (SARs) in Greater China SHANGHAI, March 12, 2026 /PRNewswire/ -- Today, Nuance Pharma ("Nuance") announced that the H...
2026-03-12 15:52
4231
Building Resilient Rare Disease Support in Malaysia with Pharm-D Health Science's VALENS Specialised Nutrition
KUALA LUMPUR, Malaysia, March 12, 2026 /PRNewswire/ -- As Malaysia commemorates National Rare Disease Day and marks the launch of the National Policy for Rare Diseases, long-term, sustainable care for individuals living with rare, complex genetic conditions is now gaining growing attention and in...
2026-03-12 10:14
6179
Precision for Medicine Continues Asia-Pacific Expansion with Opening of Japan Office
New Tokyo office strengthens local partnerships, regulatory alignment and global integrations in the world's third largest pharmaceutical market BETHESDA, Md., March 12, 2026 /PRNewswire/ -- Precision for Medicine (Precision), a global leader in biomarker-driven clinical research and development...
2026-03-12 07:50
4010
Pierre Fabre Laboratories is exploring the potential of Artificial Intelligence to launch a new generation of clinical studies in dermo-cosmetics
From 100 to 600 patients: to support patients suffering from acne, Avène, Pierre Fabre Laboratories' leading brand, is strengthening the robustness of its clinical studies via data augmentation through Artificial Intelligence. TOULOUSE, France, March 11, 2026 /PRNewswire/ -- Avène, the leading br...
2026-03-11 23:40
5579
GC Biopharma Publishes a Comprehensive Review Paper Summarizing 30 Years of Accumulated Data on Its Proprietary Varicella Vaccine Strain, 'MAV/06'
* Demonstrates effectiveness comparable to the global standard Oka strain vaccine YONGIN, South Korea, March 11, 2026 /PRNewswire/ -- GC Biopharma(006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that a review paper comprehensively analyzing the safety...
2026-03-11 13:50
5739
Alphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer
SUZHOU, China, March 11, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the appointment of Dr. Hongwei Wang as Chief Technology Officer (CTO). Dr. Wang will be responsible for the company's Process Development and Analytical Development Department, Production Department an...
2026-03-11 09:38
5023
Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026
SHANGHAI, March 10, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its financial re...
2026-03-10 18:40
6026
Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
- ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after three monthly doses. - ASC30 SQ depot formulation maintained weight loss for the four months following the third and final mon...
2026-03-10 18:00
7576
K-pop Singer and Actress Kim Sejeong Named Global Brand Ambassador for 'REJURAN' and 'REJURAN COSMETICS'
GANGNEUNG, South Korea, March 10, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd.
(CEO Jihoon Sohn) announced that singer and actress Kim Sejeong has been named
the new global brand ambassador for its flagship brands REJURAN® and REJURAN®
COSMETICS.
2026-03-10 16:03
6507
The 0.05 EU/mg Breakthrough: How Sino Biological ProPure™ Is Redefining the Ultra-Low Endotoxin Standard
HOUSTON, March 10, 2026 /PRNewswire/ -- While exotoxins dominate discussions of bacterial infections, endotoxins—cell wall components released upon bacterial death—are equally dangerous. These endotoxins trigger hyperinflammatory responses that spiral into endotoxemia, in which bloodstream endoto...
2026-03-10 15:22
4209
Codex Genetics Partners with C2N Diagnostics to Introduce the PrecivityAD2™ Blood Test in Hong Kong, Facilitating Access to Innovative Alzheimer's Disease Diagnostics
HONG KONG, March 10, 2026 /PRNewswire/ -- Codex Genetics, a leading precision diagnostics company headquartered in Hong Kong, today announces a strategic collaboration with C2N Diagnostics (C2N), a global leader in in advanced brain health diagnostics. The partnership will introduce the Precivit...
2026-03-10 09:33
5531
Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY® in Mainland China
SHANGHAI, March 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the commercial launch of VELSIPITY® (...
2026-03-09 21:27
8997
Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis
CHENGDU, China, March 9, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) and Harbour BioMed (HKEX: 02142) today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug ...
2026-03-09 19:39
5786
IgHM - A New Breakthrough in Immunonutrition
HO CHI MINH CITY, Vietnam, March 9, 2026 /PRNewswire/ -- With an orientated development based on scientific nutrition, VitaDairy (Vietnam) has officially introduced its new ColosBaby Lactoferrin - a nutritional formula, which is utilized with many superior nutrients such as a super-immune complex...
2026-03-09 19:13
3931
G-NiiB GenieBiome and Ocean Park Conclude Gut Microbiome Education Programme
Two–Year Initiative Reaches Over 200,000 Parents and Children Student Artworks Reflect Early Understanding of Gut Health HONG KONG, March 9, 2026 /PRNewswire/ -- The gut is responsible for more than digestion and is often described as the body's "second brain." Research in recent years has highli...
2026-03-09 17:10
4537
Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 9, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Kelun-Biotech (6990.HK) today announced ...
2026-03-09 16:32
6316
Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer
NANJING, China, March 9, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK)announced on March 6, 2026 that the first patient has been successfully dosed in a Phase Ⅱ clinical study evaluating Opamtistomig (LBL-024), the company's core inve...
2026-03-09 14:28
5700
Week's Top Stories
Most Reposted
TotalEnergies ENEOS Extends Solar Partnership with Ceres in Indonesia
[Picked up by 317 media titles]
2026-06-08 10:16
Visa Partners with OpenAI to Power the Next Generation of AI Commerce
[Picked up by 304 media titles]
2026-06-11 09:30QuettaFlow Technologies Strengthens Global Strategic Alliance with Lead Wealth and Showcases VasEdge at COMPUTEX Taipei 2026
[Picked up by 294 media titles]
2026-06-11 10:00
Omni HR Launches Mino, the First AI Agent Built on Unified APAC HR Data
[Picked up by 286 media titles]
2026-06-08 09:00
HKC, ANTGAMER, KOORUI Make Strong Debut at COMPUTEX 2026 with World-First Display Innovations
[Picked up by 279 media titles]
2026-06-10 11:13
Most Read
Quantinuum Announces Closing of Upsized Initial Public Offering
2026-06-06 05:08
8245
NYSE Content Update: PointFive Raises $60 Million to Redefine Efficiency
2026-06-08 20:55
7299
SynbioTech Launches SYNMUE™ Targeting Immunosenescence, to Showcase at Probiota Americas 2026 in Vancouver
2026-06-06 03:15
6683
